Do you happen to know if it is this particular trial?They expanded the number of candidates and are apparently open for recruitment again. They postponed the completion date to September, unfortunately.
@Matchbox, are you saying Kv7.1 is more important than Kv7.2/3? I read Kv7.1 is expressed in the inner ear.XEN-496 will work. The mechanism is sound as f. Hugs Kv7.1 subunits like white on rice.
XEN-1101 is pretty novel in its shape and mechanism, but same target.
Kv7.1 channels also play critical roles in the inner ear, where they mediate K+ flux across the apical membrane of the marginal cells (MCs) of the stria vascularis into the scala media of the cochlear duct.
Good question. It looks like it, but I'm not sure.Do you happen to know if it is this particular trial?
The page reads:Good question. It looks like it, but I'm not sure.
Do you believe Kv7.1 has anything to do with noxacusis? Would XEN1101 be not as useful because it only targets Kv7.2/3?@Matchbox, are you saying Kv7.1 is more important than Kv7.2/3? I read Kv7.1 is expressed in the inner ear.
I don't know what to think regarding the specific channels. I think potassium channel openers are potentially useful.Do you believe Kv7.1 has anything to do with noxacusis? Would XEN1101 be not as useful because it only targets Kv7.2/3?
Would these potassium channel openers be dangerous to people who already have visual snow?I don't know what to think regarding the specific channels. I think potassium channel openers are potentially useful.
Again, I don't know. What are the side effects from the clinical trials? Have you read them or the transcripts? I would think there's a possibility. You won't ever get a medication that is free of side effects for 100% of the population.Would these potassium channel openers be dangerous to people who already have visual snow?
Good news!Just checked up on this. Phase 1 completes 23/01/2024. 128 enrolled.